1832 Asset Management’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-2,243,600
Closed -$79.1M 864
2023
Q3
$79.1M Hold
2,243,600
0.11% 126
2023
Q2
$85.3M Hold
2,243,600
0.1% 119
2023
Q1
$84.7M Sell
2,243,600
-44,000
-2% -$1.69M 0.12% 120
2022
Q4
$96.9M Sell
2,287,600
-646
-0% -$26.6K 0.16% 117
2022
Q3
$73.5M Buy
2,288,246
+952,346
+71% +$33.4M 0.14% 142
2022
Q2
$43.4M Sell
1,335,900
-300,000
-18% -$9.72M 0.08% 198
2022
Q1
$58.4M Sell
1,635,900
-120,023
-7% -$4.12M 0.08% 194
2021
Q4
$70.7M Buy
1,755,923
+23
+0% +$959 0.13% 143
2021
Q3
$74.8M Hold
1,755,900
0.14% 132
2021
Q2
$72.7M Buy
1,755,900
+125,900
+8% +$4.86M 0.14% 144
2021
Q1
$52M Sell
1,630,000
-50,000
-3% -$1.88M 0.11% 169
2020
Q4
$68.7M Buy
1,680,000
+280,000
+20% +$10.5M 0.16% 137
2020
Q3
$52.6M Buy
1,400,000
+930,000
+198% +$33.6M 0.14% 137
2020
Q2
$15.5M Buy
470,000
+369,600
+368% +$10.1M 0.05% 209
2020
Q1
$2.07M Buy
+100,400
New +$2.24M 0.01% 410

Other funds holding GMAB

1832 Asset Management's GMAB Position: Q4 2023 in Review

1832 Asset Management sold out of Genmab (GMAB) in Q4 2023, closing a stake of 2,243,600 shares — an estimated $79.1M sold.

1832 Asset Management first reported a position in GMAB in Q1 2020 and held it in 15 quarters. The position peaked at $96.9M in Q4 2022. 226 funds tracked by Wall St. Rank hold GMAB as of Q4 2023.

  • 1832 Asset Management reported no remaining Genmab position as of Q4 2023 after selling out during the quarter.
  • 1832 Asset Management sold 2,243,600 Genmab shares in Q4 2023, an estimated $79.1M.
  • 1832 Asset Management first reported a position in Genmab in Q1 2020 and held it in 15 quarters.
  • 1832 Asset Management's Genmab position peaked at $96.9M in Q4 2022.
  • 226 funds tracked by Wall St. Rank held Genmab as of Q4 2023.

Based on 1832 Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.